Elena Corradini

List of Publications by Year
in descending order

36 papers	2,793 citations	236925 25 h-index	377865 34 g-index
37 all docs	37 docs citations	37 times ranked	2534 citing authors

#	Article	IF	Citations
1	BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nature Genetics, 2009, 41, 482-487.	21.4	678
2	STAT3 Is Required for IL-6-gp130â€“Dependent Activation of Hepcidin In Vivo. Gastroenterology, 2007, 132, 294-300.	1.3	279
3	Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin) Tj ETQq1 1 0.784314 rgBT /Overlo	1.4	187
4	Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice. Hepatology, 2011, 54, 273-284.	7.3	169
5	Bone Morphogenetic Protein Signaling Is Impaired in an Hfe Knockout Mouse Model of Hemochromatosis. Gastroenterology, 2009, 137, 1489-1497.	1.3	131
6	Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology, 2005, 128, 470-479.	1.3	129
7	Gluconeogenic Signals Regulate Iron Homeostasis via HepcidinÂinÂMice. Gastroenterology, 2014, 146, 1060-1069.e3.	1.3	111
8	Regulation of TMPRSS6 by BMP6 and iron in human cells and mice. Blood, 2011, 118, 747-756.	1.4	104
9	The RGM/DRAGON family of BMP co-receptors. Cytokine and Growth Factor Reviews, 2009, 20, 389-398.	7.2	102
10	BMP6 Treatment Compensates for the Molecular Defect and Ameliorates Hemochromatosis in Hfe Knockout Mice. Gastroenterology, 2010, 139, 1721-1729.	1.3	99
11	Non-HFEHepatic Iron Overload. Seminars in Liver Disease, 2011, 31, 302-318.	3.6	90
12	Iron Regulation of Hepcidin Despite Attenuated Smad1,5,8 Signaling in Mice Without Transferrin Receptor 2 or Hfe. Gastroenterology, 2011, 141, 1907-1914.	1.3	89
13	Kupffer cells and macrophages are not required for hepatic hepcidin activation during iron overload. Hepatology, 2005, 41, 545-552.	7.3	62
14	Magnetic resonance imaging to identify classic and nonclassic forms of ferroportin disease. Blood Cells, Molecules, and Diseases, 2006, 37, 192-196.	1.4	52
15	Iron and steatohepatitis. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 42-46.	2.8	52
16	Evaluating the association of serum ferritin and hepatic iron with disease severity in nonâ€alcoholic fatty liver disease. Liver International, 2019, 39, 1325-1334.	3.9	48
17	Molecular and clinical correlates in iron overload associated with mutations in ferroportin. Haematologica, 2006, 91, 1092-5.	3.5	43
18	Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. Journal of Hepatology, 2021, 75, 506-513.	3.7	40

#	Article	IF	Citations
19	Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study. American Journal of Gastroenterology, 2022, 117, 147-157.	0.4	39
20	Altered hepatic BMP signaling pathway in human HFE hemochromatosis. Blood Cells, Molecules, and Diseases, 2010, 45, 308-312.	1.4	36
21	Serum Ferritin as a Predictor of Treatment Outcome in Patients With Chronic Hepatitis C. American Journal of Gastroenterology, 2009, 104, 605-616.	0.4	35
22	Lack of enterocyte iron accumulation in the ferroportin disease. Blood Cells, Molecules, and Diseases, 2005, 35, 315-318.	1.4	31
23	Clinical impact of application of risk assessment models (Padua Prediction Score and Improve Bleeding) to ETQq1 1 0.784314 rgBT /Ov pharmacologic VTE prophylaxis: a â€œreal lifeâ€•prospective and retrospective observational study on patients hospitalized in a Single Internal Medicine Unit (the STIME study). Internal and Emergency Medicine, 2018, 13, 527-534.	2.0	31
24	Genetic iron overload disorders. Molecular Aspects of Medicine, 2020, 75, 100896.	6.4	28
25	Hepcidin Expression Does Not Rescue the Iron-Poor Phenotype of Kupffer Cells in Hfe-Null Mice After Liver Transplantation. Gastroenterology, 2010, 139, 315-322.e1.	1.3	26
26	Hepatitis B virus DNA integration in tumour tissue of a non-cirrhotic HFE-haemochromatosis patient with hepatocellular carcinoma. Journal of Hepatology, 2013, 58, 190-193.	3.7	26
27	Disease progression and liver cancer in the ferroportin disease. Gut, 2007, 56, 1030-1032.	12.1	24
28	Hyperhomocysteinemia in patients with acute porphyrias: A potentially dangerous metabolic crossroad?. European Journal of Internal Medicine, 2020, 79, 101-107.	2.2	22
29	Subacute copper-deficiency myelopathy in a patient with occult celiac disease. Journal of Spinal Cord Medicine, 2017, 40, 489-491.	1.4	11
30	Impact of natural neuromedinâ€Β receptor variants on iron metabolism. American Journal of Hematology, 2020, 95, 167-177.	4.1	7
31	Iron in Porphyrias: Friend or Foe?. Diagnostics, 2022, 12, 272.	2.6	4
32	Iron and the liver. Pediatric Endocrinology Reviews, 2004, 2 Suppl 2, 245-8.	1.2	4
33	Reply to: â€œCeruloplasmin variants might have different effects in different iron overload disordersâ€• Journal of Hepatology, 2021, 75, 1004-1006.	3.7	2
34	Can Disruption of Basal Ganglia-Thalamocortical Circuit in Wilson Disease Be Associated with Juvenile Myoclonic Epilepsy Phenotype?. Brain Sciences, 2022, 12, 553.	2.3	2
35	Method for Measuring Macrophage Iron Efflux in Vitro and in Vivo Using Magnetic Resonance Imaging. Blood, 2008, 112, 4636-4636.	1.4	0
36	Hereditary Hemochromatosis. , 2006, , 567-572.		0